nCounter® PanCancer Immune Profiling Panel

Helping Your Research

Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.

Comprehensive profiling of the immune response optimized for immuno-oncology research
Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
Assess mechanistic pathway activity for single or combination studies
Customizable with up to 55 additional user-defined genes with Panel Plus option
Multi-analyte analysis with Vantage 3D™ Assays

The nCounter PanCancer Immune Profiling Panel is for cancer researchers that need more markers than is practical for RT-qPCR but don’t want the broad approach that next-gen sequencing (NGS) offers. The Panel is fully compatible with clinically relevant sample types such as fresh-frozen (FF) tissue, formalin-fixed, paraffin-embedded (FFPE) tumor sections, isolated immune cell populations such as PBMCs, and cell lysates. The panel may be used in conjunction with nCounter Panel Plus products for additional flexibility in experimental design.

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Immune Cell Type Gene Coverage

Product Specifications

Product Comparison

Immune Cell Type Gene Coverage

Product Specifications

Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

View All Related Resources

Product Bulletin Hallmarks of Cancer – Product Bulletin

Whitepaper Multiplexed Cancer Immune Response Analysis – Whitepaper

Publications

View All Publications

Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment.

The tumor microenvironment (TME) harbors heterogeneous contents and plays critical roles in tumorigenesis, metastasis, and drug resistance. Therefore, the deconvolution of the TME becomes increasingly essential to every aspect of cancer research and treatment.

Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.

Tumors evade immune surveillance by expressing Programmed Death-Ligand 1 (PD-L1), subsequently inhibiting CD8+ cytotoxic T lymphocyte function. Response of gastric cancer to immunotherapy is relatively low.

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality.

Immunotherapy has reshaped the field of cancer therapeutics but the population that benefits are small in many tumor types, warranting a companion diagnostic test. While immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) or mismatch repair (MMR) and polymerase chain reaction (PCR) for microsatellite instability (MSI) are the only approved companion diagnostics others are under consideration.